Two FDA advisory committees voted in favor of the approval of Purdue Pharma’s reformulated version of long-acting OxyContin, despite some members’ concerns over the drug’s safety. The OxyContin drug designed to be abuse-deterrent. The reformulated version of OxyContin (oxycodone HCl) would be slightly safer than the current product, although its safety profile for the majority of users is still doubtful, according to David Margolis, the professor of dermatology and epidemiology at the University of Pennsylvania.